AHR agonist 4 is a lead compound for anti-psoriatic drugs, capable of alleviating imiquimod (IMQ)-induced psoriasis-like skin lesions; it modulates immune balance related to Th17/22 and Treg cells; it serves as a click chemistry reagent containing an alkyne group that undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing molecules.